Jakafi (ruxolitinib) is a type of JAK inhibitor that is used to treat myelofibrosis. Jakafi does not cure myelofibrosis, but can help to control the symptoms of the disease and slow down its progression. The exact cause of myelofibrosis is not known, but it is thought to occur as a result of mutations in the bone marrow cells.
Jakafi works by blocking the activity of specific proteins called Janus kinases (JAKs), which play a role in regulating the activity of the immune system and the production of blood cells.
In myelofibrosis, the activity of JAKs is thought to be dysregulated, which contributes to its development. By blocking JAKs, Jakafi can help to relieve symptoms, and can also help to slow down the progression of the disease.
There is ongoing research aimed at gaining a deeper understanding of the underlying mechanisms and the role of JAKs in the development and progression of the disease. Nevertheless, Jakafi has been shown to be effective in relieving symptoms and slowing down the progression of myelofibrosis in some patients, making it an important treatment option for individuals with this disease.
| Quantity | 10mg, 15mg, 20mg, 5mg |
|---|
Be the first to review “Jakafi” Cancel reply
Related products
Chemotherapy
$100.00 – $7,500.00
Chemotherapy
$107.00
Chemotherapy
$22.00
Chemotherapy
$1,200.00
Chemotherapy
$1,800.00








Reviews
There are no reviews yet.